Spero Therapeutics, Inc. (SPRO) Income Statement
SPRO 2025 at a glance
Fiscal year ended December 31, 2025 · U.S. dollarsSPRO revenue and net income
Where SPRO's revenue goes
2025Each bar shows an amount and its share of revenue. SPRO kept 14.4% of revenue as net income.
SPRO profit margins
SPRO growth rates
to 2025| 1 year | 3 years | 5 years | 10 years | |
|---|---|---|---|---|
| Revenue | +24.3% | +7.1% | +44.9% | — |
| Gross profit | — | +7.1% | +44.9% | — |
| Operating income | — | — | — | — |
| Net income | — | — | — | — |
| EPS (diluted) | — | — | — | — |
1-year change and average annual growth (CAGR) over 3, 5 and 10 fiscal years. "—" when a starting value was zero or negative.
SPRO quarterly EPS vs estimates
Spero Therapeutics beat the analyst EPS estimate in 5 of the last 6 quarters. Next report: November 12, 2026 (estimate $-0.14).
SPRO income statement
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $59.6M | $48.0M | $103.8M | $48.6M | $3.1M | $9.3M | $4.7M | $4.0M | $2.0M | $335,000 |
| Cost of revenue | $0 | $96.8M | $51.4M | $1.5M | $1.1M | $67.0M | $65.8M | $33.9M | $32.9M | $26.3M |
| Gross profit | $59.6M | −$48.8M | $52.3M | $48.6M | $3.1M | $9.3M | $4.7M | $4.0M | $2.0M | −$26.0M |
| Research & development | $38.5M | $96.8M | $51.4M | $47.6M | $64.5M | $67.0M | $65.8M | $33.9M | $32.9M | $26.3M |
| Sales, general & admin | $21.2M | $22.9M | $25.0M | $36.5M | $41.7M | $21.9M | $15.6M | $12.9M | $10.8M | $7.2M |
| Total operating expenses | $59.6M | $24.6M | $30.9M | $90.8M | $91.0M | $88.4M | $68.0M | $42.8M | $41.7M | $33.6M |
| Operating income | −$24,000 | −$73.4M | $21.5M | −$42.2M | −$88.0M | −$79.1M | −$63.2M | −$42.8M | −$41.7M | −$33.2M |
| Interest income | $2.5M | $4.7M | $3.9M | $1.1M | $346,000 | $401,000 | $1.3M | $1.1M | $303,000 | $0 |
| Interest expense | — | — | $0 | $2.6M | $1.9M | $0 | $0 | $303,000 | $303,000 | $0 |
| Income before taxes | $8.8M | −$68.6M | $25.4M | −$46.4M | −$89.8M | −$78.3M | −$60.9M | −$41.7M | −$46.1M | −$32.6M |
| Income taxes | $261,000 | — | $2.6M | $1.6M | $1.5M | −$761,000 | −$750,000 | $1.1M | −$363,000 | −$7.7M |
| Net income | $8.6M | −$68.6M | $22.8M | −$46.4M | −$89.8M | −$77.5M | −$60.2M | −$41.7M | −$46.1M | −$25.5M |
| EBITDA | $8.8M | −$72.5M | $27.2M | −$42.9M | −$87.2M | −$78.4M | −$62.5M | −$42.4M | −$41.4M | −$32.9M |
| EPS (diluted) | $0.12 | −$1.26 | $0.52 | −$1.22 | −$2.89 | −$3.58 | −$3.34 | −$42.12 | −$3.44 | −$3.86 |
| Gross margin | 100.0% | −101.7% | 50.4% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | −7,760.6% |
| Operating margin | −0.0% | −152.9% | 20.7% | −86.9% | −2,865.5% | −847.9% | −1,333.1% | −1,079.3% | −2,108.6% | −9,916.7% |
| Net margin | 14.4% | −142.9% | 22.0% | −95.5% | −2,923.6% | −830.9% | −1,269.0% | −1,050.5% | −2,329.3% | −7,609.3% |
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 | Jun '24 | Mar '24 | Dec '23 | Sep '23 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $258,000 | $39.7M | $3.0M | $11.8M | $5.9M | $15.0M | $13.5M | $10.2M | $4.2M | $73.5M | $25.5M |
| Cost of revenue | — | $0 | $0 | $0 | $0 | $13.6M | $94.6M | $2,000 | $23.7M | −$5.1M | $49.4M | $619,000 |
| Gross profit | — | $258,000 | $39.7M | $3.0M | $11.8M | −$7.7M | −$79.6M | $13.5M | −$13.5M | $4.2M | $24.1M | $24.9M |
| Research & development | $3.4M | $2.9M | $5.6M | $8.6M | $10.7M | $13.6M | $28.8M | $26.9M | $23.7M | $17.3M | $16.6M | $16.4M |
| Sales, general & admin | $6.5M | $4.9M | $4.3M | $4.2M | $5.9M | $6.8M | $6.3M | $5.2M | $5.5M | $5.9M | $5.9M | $5.7M |
| Total operating expenses | $9.9M | $7.8M | $8.3M | $11.0M | $14.2M | $7.0M | −$57.9M | $32.1M | $5.5M | $18.2M | −$26.4M | $26.8M |
| Operating income | −$9.9M | −$7.5M | $31.4M | −$7.9M | −$2.4M | −$14.7M | −$21.7M | −$18.6M | −$19.1M | −$14.0M | $50.5M | −$1.9M |
| Interest income | $377,000 | $336,000 | $376,000 | $532,000 | $740,000 | $864,000 | $1.0M | $1.2M | $1.2M | $1.3M | $1.0M | $950,000 |
| Interest expense | — | — | — | — | — | — | — | — | — | — | $961,000 | $0 |
| Income before taxes | −$9.6M | −$7.2M | $31.8M | −$7.4M | −$1.7M | −$13.9M | −$20.6M | −$17.4M | −$17.9M | −$12.7M | $51.6M | −$994,000 |
| Income taxes | — | — | $261,000 | — | — | — | $290,000 | −$290,000 | — | −$91,750 | $387,000 | $2.2M |
| Net income | −$9.6M | −$7.2M | $31.5M | −$7.4M | −$1.7M | −$13.9M | −$20.9M | −$17.1M | −$17.9M | −$12.7M | $51.2M | −$3.2M |
| EBITDA | −$9.6M | −$7.2M | $31.8M | −$7.3M | −$2.4M | −$14.6M | −$20.8M | −$17.4M | −$17.9M | −$12.7M | $51.6M | $3.5M |
| EPS (diluted) | −$0.16 | −$0.13 | $0.53 | −$0.13 | −$0.03 | −$0.25 | −$0.37 | −$0.32 | −$0.33 | −$0.24 | $0.96 | $0.04 |
| Gross margin | — | 100.0% | 100.0% | 100.0% | 100.0% | −131.6% | −529.0% | 100.0% | −132.7% | 100.0% | 32.8% | 97.6% |
| Operating margin | — | −2,921.7% | 79.2% | −259.7% | −20.7% | −250.8% | −144.4% | −138.0% | −186.9% | −332.6% | 68.7% | −7.6% |
| Net margin | — | −2,791.9% | 79.5% | −242.2% | −14.4% | −236.1% | −138.8% | −127.3% | −175.2% | −301.4% | 69.6% | −12.6% |
Quarterly columns are labeled by the month the quarter ended. Figures in U.S. dollars as reported in SPRO's financial statements (latest annual report filed March 26, 2026); data from EODHD. Sales, general & administrative expenses include sales and marketing.
SPRO financial results
In fiscal year 2025 (ended December 31, 2025), Spero Therapeutics reported revenue of $59.6 million, up 24.3% from the year before. It had net income of $8.6 million, a net profit margin of 14.4%. Diluted earnings per share came to $0.12. Over five years revenue grew at an average rate of 44.9% a year.
See the SPRO stock overview for the latest quote and news, or the SPRO chart for price history and technical indicators.
SPRO income statement FAQ
What is Spero Therapeutics's annual revenue?
Spero Therapeutics reported total revenue of $59.6 million for fiscal year 2025, which ended on December 31, 2025. That was up 24.3% from $48.0 million the previous year.
Is Spero Therapeutics profitable?
Yes. Spero Therapeutics reported net income of $8.6 million in fiscal 2025, a net profit margin of 14.4%; its operating margin was −0.0%.
What is Spero Therapeutics's gross margin?
Spero Therapeutics's gross margin was 100.0% in fiscal 2025: for every $100 of revenue, Spero Therapeutics kept $100 after the direct cost of its products and services.
How much does Spero Therapeutics spend on research and development?
Spero Therapeutics spent $38.5 million on research and development in fiscal 2025, 64.5% of revenue.
How fast is Spero Therapeutics growing?
Revenue grew 44.9% a year on average over the last five fiscal years, from $9.3 million to $59.6 million.
What are Spero Therapeutics's earnings per share?
Spero Therapeutics earned $0.12 per diluted share in fiscal 2025, compared with $-1.26 a year earlier.
When will Spero Therapeutics report its next earnings?
Spero Therapeutics is expected to report results for the quarter ending September 30, 2026 on November 12, 2026 after the market closes.
When does Spero Therapeutics's fiscal year end?
Spero Therapeutics's fiscal year ends in December. The latest annual report covers the year ended December 31, 2025 and was filed on March 26, 2026.